Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04928066
Recruitment Status : Recruiting
First Posted : June 16, 2021
Last Update Posted : June 18, 2021
Sponsor:
Information provided by (Responsible Party):
Qiang Shu, Qilu Hospital of Shandong University

Brief Summary:
RA is a common autoimmune disease that causes joint damage.It is necessary to reach the standard as soon as possible and give effective drugs according to the patient's disease activity to avoid disability. Tofacitinib(TF) is a new type of oral tyrosine kinase inhibitor (JAKi) for the treatment of moderate to severe active RA. However, there is alack of Chinese data on the joint scheme, long-term use, maintenance and stop of TF in the real world. We will use the new JAK combination regimen to treat RA patients, and carry out long-term clinical follow-up for 30 weeks.

Condition or disease Intervention/treatment Phase
Arthritis, Rheumatoid Drug: Iguratimod Drug: Tofacitinib Drug: Pred Phase 4

Detailed Description:
Objective: To observe the clinical efficacy and safety of TF combined with/ without IGU for 30 weeks in patients with moderate to severe active RA with different clinical characteristics and subgroups by using a prospective cohort , and to find the best combination scheme of TF.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Tofacitinib (TF) Combined With Iguratimod(IGU) in the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)
Actual Study Start Date : March 1, 2020
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Tofacitinib (TF)+Iguratimod (IGU)

Drug: Iguratimod(IGU),25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.

Drug: Tofacitinib(TF),5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.

Drug: Prednisone (Pred): 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.

Drug: Iguratimod
Iguratimod tablet,25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Other Names:
  • IGU
  • T-614

Drug: Tofacitinib
Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Other Name: TF

Drug: Pred
Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
Other Name: Prednisone

Tofacitinib (TF)

Drug: Tofacitinib(TF),5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.

Drug: Prednisone (Pred): 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.

Drug: Tofacitinib
Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Other Name: TF

Drug: Pred
Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
Other Name: Prednisone




Primary Outcome Measures :
  1. The percentage of patients who achieve clinical remission at week 30 using European League Against Rheumatism (EULAR) response criteria DAS28 [ Time Frame: week 30 ]
    The percentage of patients whose Disease Activity Score in 28 Joints (DAS28) achieve remission(DAS28-ESR≤ 2.6)and Low Disease Activity (DAS28-ESR ≤ 3.2). The DAS28 is a composite score derived from 4 of these measures,that is the count of tender joint count(TJC, 0-28)and swollen joint count(SJC, 0-28), measure erythrocyte sedimentation rate (ESR, mm/h) or C reactive protein (CRP, mg/L) and to make a patient assessment of disease activity i.e. 'global assessment of health' (GH) using a 100 mm visual analogue scale (VAS) with 0 = best, 100 = worst. DAS28 values were calculated as follows: DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x GH. High disease activity: DAS28-ESR > 5.1; Moderate disease activity: 5.1≥ DAS28 > 3.2 to 5.1; Low disease activity (LDA) and Remission mean Clinical remission.


Secondary Outcome Measures :
  1. The percentage of patients who achieve clinical remission using DAS28-ESR at week 18 [ Time Frame: week 18 ]
    The percentage of patients whose DAS28 achieve remission(DAS28-ESR≤ 2.6)and Low Disease Activity (DAS28-ESR ≤ 3.2) at week 18.

  2. The percentage of patients who achieve clinical remission using DAS28-ESR at week 6 [ Time Frame: week 6 ]
    The percentage of patients whose DAS28 achieve remission(DAS28-ESR≤ 2.6)and Low Disease Activity (DAS28-ESR ≤ 3.2) at week 18.

  3. Percentage of Disease Activity Score 28 (DAS28) -ESR Criteria Responders at week 30 [ Time Frame: week 30 ]
    △DAS28 indicates the decline of DAS28-ESR from the baseline to week 30. EULAR response states were classified as follows: good responders were patients with an improvement from baseline (△DAS28-ESR) of > 1.2 and a DAS28-ESR at week 30 ≤ 3.2. Moderate responders: △DAS28 > 1.2 and still DAS28 > 3.2 at week 30, or 1.2 ≥△DAS28 > 0.6 and DAS28 ≤ 5.1 at week 30. Nonresponders:△DAS28 ≤0.6 or DAS28 >5.1 at week 30. DAS28-defined remission was classified as a score of <2.6.

  4. Percentage of Disease Activity Score 28 (DAS28) -ESR Criteria Responders at week 18 [ Time Frame: week 18 ]
    EULAR response states were classified as follows: DAS28-ESR Good responders: △DAS28 > 1.2 and DAS28 ≤3.2 at week 18. Moderate responders:△DAS28 > 1.2 and still DAS28 > 3.2 at week 18; or 1.2 ≥△DAS28 > 0.6 and DAS28 ≤ 5.1 at week 18. Nonresponders:△DAS28 ≤0.6,or DAS28 >5.1 at week 18. DAS28-defined remission was classified as a score of <2.6.

  5. Percentage of Disease Activity Score 28 (DAS28) -ESR Criteria Responders at week 6 [ Time Frame: week 6 ]
    EULAR response states were classified as follows: DAS28-ESR Good responders: △DAS28 > 1.2 and DAS28 ≤3.2 at week 6. Moderate responders:△DAS28 > 1.2 and still DAS28 > 3.2 at week 6; or 1.2 ≥△DAS28 > 0.6 and DAS28 ≤ 5.1 at week 6. Nonresponders:△DAS28 ≤0.6,or DAS28 >5.1 at week 6. DAS28-defined remission was classified as a score of <2.6.

  6. Percentage of participants achieving ACR/EULAR remission at week 30 [ Time Frame: week 30 ]
    If all of the following 4 parameters are fulfilled, it is defined as remission: TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dL, Patient global assessment(PGA) ≤ 1 cm (on a visual analog scale ranging from 0-10 cm, with higher scores indicating severe disease).

  7. Percentage of participants achieving ACR/EULAR remission at week 18 [ Time Frame: week 18 ]
    If all of the following 4 parameters are fulfilled, it is defined as remission: TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dL, Patient global assessment(PGA) ≤ 1 cm (on a visual analog scale ranging from 0-10 cm, with higher scores indicating severe disease).

  8. Percentage of participants achieving ACR/EULAR remission at week 6 [ Time Frame: week 6 ]
    If all of the following 4 parameters are fulfilled, it is defined as remission: TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dL, Patient global assessment(PGA) ≤ 1 cm (on a visual analog scale ranging from 0-10 cm, with higher scores indicating severe disease).

  9. Change from baseline Simplified Disease Activity Index (SDAI) [ Time Frame: up to week 30 ]
    The SDAI is a composite score derived from these measures,that is the count of tender joint count(TJC, 0-28), swollen joint count(SJC, 0-28), C-reactive protein (CRP, mg/L), Patient global assessment(PGA)and physician global assessment(PHGA), each of the last two was assessed on a visual analog scale ranging from 0-10 cm, with higher scores indicating severe disease. SDAI score will be calculated with formula SDAI = TJC + SJC + PGA+PHGA+ CRP. SDAI score exceeding 26 is considered high disease activity; 11 <SDAI ≤26,moderate disease activity; 3.3 <SDAI ≤11, low disease activity; remission is SDAI score ≤ 3.3.

  10. Change from baseline Clinical Disease Activity Index (CDAI) [ Time Frame: up to week 30 ]
    Change from baseline Clinical Disease Activity Index (CDAI) CDAI is a composite score derived from these measures,that is the count of tender joint count(TJC, 0-28), swollen joint count(SJC, 0-28), Patient global assessment(PGA)and physician global assessment(PHGA), each of the last two was CDAI score will be calculated with formula CDAI = TJC + SJC + PGA + PHGA. CDAI > 22 is considered high disease activity; 10 <CDAI ≤ 22, moderate disease activity; 2.8 <CDAI ≤10, low disease activity; remission is CDAI score ≤2.8.

  11. Change From Baseline in C-reactive Protein (CRP) [ Time Frame: up to week 30 ]
    Change from Baseline in C-reactive Protein (CRP), a component index of ACR20 and SDAI, CRP will be measured with blood samples.

  12. Change From Baseline in Erythrocyte Sedimentation Rate (ESR) [ Time Frame: up to week 30 ]
    Change from Baseline in ESR, that is a component index of ACR20, DAS28-ESR and SDAI, ESR will be measured with blood samples.

  13. Change from baseline Health Assessment Questionnaire Disability Index (HAQ-DI) [ Time Frame: up to week 30 ]
    Change from Baseline in HAQ-DI, a participant assessed measure of health assessment, shaveing eight dimensions of functional activity: pruning, dressing, rising, eating, walking, personal hygiene, reach, grip, and other routine activities. Each item on a single scale has 4 degrees ranging from 0 (no functional difficulty) to 3 (unable to do), with higher scores indicating severe disease.

  14. Percentage of American College of Rheumatology [ACR] 20 Criteria Responders every time [ Time Frame: up to week 30 ]
    Percentage of American College of Rheumatology [ACR] 20 Criteria Responders every time

  15. Incidence of participant withdrawal [ Time Frame: up to week 30 ]
    Percentage of participants who withdraw from this study.

  16. Number of participants with"adverse events (AEs)" [ Time Frame: up to week 30 ]
    An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with"adverse events (AEs)"i.e. physical exam abnormalities,vital sign abnormalities,laboratory value abnormalities,symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients who meet the following inclusion criteria will be eligible to participate in the study:

  1. Patients who meet RA standards in 1987 and 2010 or ERA standards in 2012;
  2. Age > 18 years old;
  3. the extrapulmonary manifestations of RA were stable;
  4. Patients with NSAIDs tolerance;
  5. DAS28-ESR is highergreater than 2.6.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study:

  1. Patients with acute and chronic infection;
  2. Platelet count < 80*10^9/L, or white blood cell < 3*10^9/L;
  3. ALT or AST is 2 times higher than the upper limit of normal value;
  4. Renal insufficiency: serum Cr ≥ 176 umol/L;
  5. Pregnant or lactating women (breastfeeding);
  6. Have a history of malignant tumor (the cure time is less than 5 years);
  7. Patients with severe hypertension and cardiac insufficiency;
  8. Other diseases or conditions in which immune suppressants cannot be used;
  9. People who are allergic to TF.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04928066


Contacts
Layout table for location contacts
Contact: Qiang Shu, Dr. 0086-0531-82169654 shuqiang@sdu.edu.cn
Contact: Xiaoyan Qi 0086-0531-82169654 sdqixiaoyan@163.com

Locations
Layout table for location information
China, Shandong
Qilu Hospital Recruiting
Jinan, Shandong, China, 250012
Contact: Xiaoyun Yang, Dr.    0086-0531-82169166    qlyykyc@163.com   
Sponsors and Collaborators
Qilu Hospital of Shandong University
Investigators
Layout table for investigator information
Study Director: Xiaoyun Yang, Dr. Qilu Hospital of Shandong University
Layout table for additonal information
Responsible Party: Qiang Shu, Chief Physician, Qilu Hospital of Shandong University
ClinicalTrials.gov Identifier: NCT04928066    
Other Study ID Numbers: Tofacitinib-RA QiluH
First Posted: June 16, 2021    Key Record Dates
Last Update Posted: June 18, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Qiang Shu, Qilu Hospital of Shandong University:
Tofacitinib
Iguratimod
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Prednisone
Tofacitinib
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action